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Abstract
A cell surface receptor for thyroid hormone that activates extracellular regulated kinase (ERK) 1/2 has been identified on
integrin avb3. We have examined the actions of thyroid hormone initiated at the integrin on human NCI-H522 non-small
cell lung carcinoma and NCI-H510A small cell lung cancer cells. At a physiologic total hormone concentration (10
27 M), T4
significantly increased proliferating cell nuclear antigen (PCNA) abundance in these cell lines, as did 3, 5, 39-triiodo-L-
thyronine (T3) at a supraphysiologic concentration. Neutralizing antibody to integrin avb3 and an integrin-binding Arg-Gly-
Asp (RGD) peptide blocked thyroid hormone-induced PCNA expression. Tetraiodothyroacetic acid (tetrac) lacks thyroid
hormone function but inhibits binding of T4 and T3 to the integrin receptor; tetrac eliminated thyroid hormone-induced
lung cancer cell proliferation and ERK1/2 activation. In these estrogen receptor-a (ERa)-positive lung cancer cells, thyroid
hormone (T4.T3) caused phosphorylation of ERa; the specific ERa antagonist ICI 182,780 blocked T4-induced, but not T3-
induced ERK1/2 activation, as well as ERa phosphorylation, proliferating-cell nuclear antigen (PCNA) expression and
hormone-dependent thymidine uptake by tumor cells. Thus, in ERa-positive human lung cancer cells, the proliferative
action of thyroid hormone initiated at the plasma membrane is at least in part mediated by ERa. In summary, thyroid
hormone may be one of several endogenous factors capable of supporting proliferation of lung cancer cells. Activity as an
inhibitor of lung cancer cell proliferation induced at the integrin receptor makes tetrac a novel anti-proliferative agent.
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Introduction
Thyroid hormone has important roles in regulation of cellular
metabolism and of cell proliferation and differentiation [1,2]. The
hormone, usually as 3, 5, 39-triiodo-L-thyronine (T3), stimulates
proliferation of a variety of nonmalignant cells, including hepatocytes
[3,4], renal tubular epithelial cells and bone marrow cells [5]. It may
inhibit proliferation of certain cells, e.g., fetal cardiomyocytes [6]. We
have shown that thyroid hormones induce cell proliferation of several
cancer cell lines, including those of breast [7], glioma [8], and the
thyroid [9]. Blood vessel cell proliferation is also stimulated by
iodothyronines [10]. The thyroid hormone L-thyroxine (T4)
at physiologic concentrations stimulates angiogenesis and cancer cell
proliferation, whereas supraphysiologic levels of T3 appear to
be required to cause proliferation of such cells [8,9]. In the case of
estrogen receptor (ER)-positive breast cancer cells, we have described
dependence of the proliferative effect of thyroid hormone on induction
of mitogen-activated protein kinase-dependent serine phosphorylation
of ERa that mimics the effect of estrogen [7]. This effect of thyroid
hormone can be blocked by the estrogen receptor antagonist, ICI
182,780. Thus, there may be crosstalk between thyroid hormone and
estrogen signaling pathways in certain cancer cells; these pathways
originate nongenomically outside the nucleus and require ERK1/
ERK2, but culminate in specific intranuclear events.
We have recently described a cell surface receptor for thyroid
hormone on integrin avb3 [11] that is linked to activation of
ERK1/ERK2 (extracellular signal regulated kinase 1/2 [ERK1/2])
and, downstream of ERK1/ERK2, to complex transcriptional
events, such as tumor cell proliferation [8] and angiogenesis [10].
The integrin is a structural protein of the plasma membrane
primarily expressed by rapidly-proliferating cells, namely, cancer
cells [12] and dividing blood vessel cells [13,14]. The protein is
essential to the interactions of these cells with extracellular matrix
proteins and growth factors [15]. The thyroid hormone receptor is
situated near the arginine-glycine-aspartic acid (Arg-Gly-Asp,
RGD) recognition site on the integrin [11,15,16]. Thus, RGD
peptides may interfere selectively with certain thyroid hormone
actions initiated at the integrin receptor [17]. At the integrin
receptor, tetraiodothyroacetic acid (tetrac) competes with T4 and T3
to inhibit integrin-initiated actions of the hormones [11,18].
Derived from T4, tetrac is exclusively an inhibitor at the cell
surface, but within the cell it has modest thyromimetic activity [19].
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e27547In the experiments reported here, thyroid hormone is shown to
induce human lung cancer cell proliferation via crosstalk between
integrin avb3a n dE R a. Tetrac consistently blocks this action in two
lung cancer cell lines. An estrogen antagonist, ICI 182,780, inhibited
integrin av binding with ERa promoter in the ChIP assay and
inhibited ERK1/ERK2 activation and cell proliferation in ERa-
bearing lung cancer cells. These results suggest that thyroxine-
induced cell proliferation occurs via crosstalk between integrin avb3
and ICI 182,780-sensitive signal transduction pathways.
Materials and Methods
Cell lines
Human non-small cell lung carcinoma cell line NCI-H522
(ATCC CRL-5810), human small cell lung cancer NCI-H510A
(ATCC HTB-184) cells and human ovarian cancer cell line,
OVCAR-3, were purchased from ATCC (Rockville, MD). Cells
were grown in F12 (NCI-510A) or in RPMI medium (NCI-H522),
supplemented with 10% FBS. OVCAR-3 cells were maintained in
RPMI1640 supplemented with 20% FBS and insulin. Cells were
maintained in a 5% CO2/95% O2 incubator at 37uC. Prior to
treatment, cells were exposed for 2 d to medium that contained
0.25% hormone-stripped fetal bovine serum (FBS).
Reagents and antibodies
T4,T 3, tetrac and RGD and RGE peptide were obtained from
Sigma Chemical Co. (St. Louis, MO). Polyclonal rabbit anti-
phosphoERK1/ERK2 (anti-pERK1/pERK2) was purchased
from Cell Signaling (Beverly, MA) and monoclonal mouse anti-
Figure 1. Thyroid hormone stimulates growth of human lung cancer cells in a concentration-dependent manner. A. Human non-small
cell carcinoma NCI-H522 cells were seeded in 10 mL Petri dishes and cultured in medium containing 0.25% thyroid hormone-depleted and estrogen-
depleted serum for 2 d prior to treatment with L-thyroxine (T4,1 0
29–10
26 M) for 24 h. T4-induced PCNA accumulation was hormone concentration-
dependent. Lamin-B immunoblots served as loading controls for the nuclear fractions in these studies and are shown in this figure and the following
figures. Reproduced results were conducted from 3 experiments for all experiments. *p,0.05,* * p,0.01 compared with control. B. Cells were similarly
cultured with 3, 5, 39-triiodo-L-thyronine (T3,1 0
29–10
26 M) for 24 h. The T3 effect on PCNA accumulation was also concentration-dependent.
*p,0.05,* * p,0.01 compared with control. C. Human non-small lung cancer NCI-H522 cells and human small cell lung cancer NCI-H510A cells were
treated with T4 (10
28 to 10
26 M) or T3 (10
29 to 10
27 M). [
3H]-Thymidine was added with hormone for 24 h prior to harvest for assay of thymidine
incorporation. In these studies, both hormones stimulated thymidine incorporation. At physiologic total hormone concentrations, however, T4
(10
27 M) was more effective than T3 (#10
29 M). (*p,0.05,* * p,0.01 compared with untreated controls.) D. Total RNA was extracted from OVCAR-3,
NCI-H522 and NCI-H510A cells and prepared for RT-PCR as described in Materials and Methods. OVCAR-3 cells served as positive controls. Both NCI-
H522 and NCI-H510A cells expressed integrin avb3, although NCI-H510A cells expressed less b3 than NCI-H522 cells.
doi:10.1371/journal.pone.0027547.g001
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Santa Cruz (Santa Cruz, CA). Monoclonal mouse anti-ERa,
polyclonal rabbit anti-ERb, monoclonal mouse anti-avb3, and
monoclonal mouse anti- avb5 were purchased from Santa Cruz
(Santa Cruz, CA). Goat anti-rabbit IgG and rabbit anti-mouse
IgG were obtained from Dako (Carpenteria, CA). The chemilu-
minescence reagent was from ECL (Amersham, Piscataway, NJ).
Cell fractionation
Fractionation of cells in a microfuge and preparation of
nucleoproteins was by our previously reported methods [20]. Nuclear
extracts were prepared by resuspension of the crude nuclei in high salt
buffer (hypotonic buffer, 420 mM NaCl and 20% glycerol) at 4uC
with rocking for 1 h. The supernatants were collected after
subsequent centrifugation at 4uC and 13,000 rpm for 10 min.
Immunoblotting
The immunoblotting techniques have been standardized in our
laboratory [19,20]. In brief, nucleoproteins were separated on
discontinuous SDS-PAGE and then transferred by electroblotting
to nitrocellulose membranes (Millipore, Bedford, MA). After
blocking with 5% milk in Tris-buffered saline containing 0.1%
Tween, the membranes were incubated with various antibodies
overnight. Secondary antibodies were either goat anti-rabbit
IgG (1:1000) (Dako, Carpenteria, CA) or rabbit anti-mouse IgG
(1:1000) (Dako), depending upon the origin of the primary
antibody. Immunoreactive proteins were detected by chemilumi-
nescence. Blots were quantitated densitometrically.
RT-PCR
Total RNA was isolated as described previously [9,10,11]. First
strand complementary DNAs were synthesized from 1 mg of total
RNA using oligo dT and AMV Reverse Transcriptase (Promega,
Madison, WI). First-strand cDNA templates were amplified
for GAPDH and COX-2 mRNAs by polymerase chain reaction
(PCR), using a hot start (Ampliwax, Perkin Elmer, Foster City,
CA). Primer sequences were integrin av (59- TGGGATTGTGGAAG-
GAG-39 and 59-AAATCCCTGTCCATCAGCAT-39 [reverse],
amplicon size: 329), integrin b3 (59-TGCCTCAACAATGAGGT-
CATCCCT-39 [forward] and 59-AGACACATTGAC CACAGA-
GGCACT-39[reverse], amplicon size: 515), ERa(59ACAAGGGAA-
GTATGGCTATGGA 39 [forward] and 59 GGTCTTTTCGTAT-
CCCACCTTTC 39 [reverse], amplicon size: 267), ERb (59-AAAG-
CCAAGAGAAACGGTGGGCAT-39 [forward] and 59-GCCAAT-
CATGTGCACCAGTTCCT-39 [reverse], amplicon size: 352) and
GAPDH (59-AAGGTCATCCCTGAGCTGAACG-39 [forward]
and 59-GGGTGTCGCTGTTGAAGTCAGA-39 [reverse], am-
plicon size: 212). The PCR cycle was an initial step of 95uCf o r
3 min, followed by 94uC for 1 min, 55uC for 1 min, 72uCf o r
1 min, then 25 cycles and a final cycle of 72uCf o r8m i n .P C R
products were separated by electrophoresis through 2% agarose
gels containing 0.2 mg of ethidium bromide/ml. Gels were
visualized under UV light and photographed with Polaroid film
(Polaroid Co., Cambridge, MA). Photographs were scanned
under direct light for quantitation and illustration. Results from
PCR products were normalized to the GAPDH signal.
Chromatin immunoprecipitation and quantitative PCR
ChIP was performed using the EZ ChIP kit (Millipore, MA)
according to the manufacturer’s instructions. Formaldehyde was
directly added to the medium (final concentration 1%) for 10 min
to crosslink nuclear proteins with genomic DNA. Then 1.25 M
glycine was added for 5 minutes. Cells were washed twice in PBS
before being scraped in 1 mL PBS with protease inhibitors (PI)
(Complete Mini protease inhibitor cocktail tablets, Roche, IN).
Cells were centrifuged for 5 min at 7006g and re-suspended in
1 mL of SDS lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris,
Figure 2. Tetrac inhibits thyroid hormone-induced PCNA
accumulation and ERK1/2 activation in different lung carcino-
ma cells. A. non-small cell NCI-H522 and B. small cell NCI-H510A lung
carcinoma cells were treated with tetrac (10
27 M) for 30 min prior to
addition of T3 (10
27 M) or T4 (10
27 M). Cells were harvested either
30 min (ERK1/2) or 24 h (PCNA) after the onset of treatment. Tetrac,
alone, did not induce either ERK1/2 activation or PCNA expression;
however, tetrac did block the effects of both T4 and T3 in these two cell
lines by inhibition of thyroid hormone binding to the cell surface
integrin receptor. *p,0.05,* * p,0.01 compared with control; +p,0.05,
++p,0.01 comparing hormone effects with and without tetrac.
doi:10.1371/journal.pone.0027547.g002
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supernatant contained DNA fragments ranging from ,200–
1000 bp. Samples were diluted (1:10) in ChIP dilution buffer
(16.7 mM Tris-HCl, pH 8.1; 0.01% SDS; 1.1% Triton X-100,
167 mM NaCl, and 1.2 mM EDTA) containing PI. Samples were
pre-cleared with a Protein G Agarose/salmon sperm DNA slurry
for 1 h at 4uC. The agarose was pelleted and the supernatant was
removed with 10 ml set aside as the ‘‘Input’’. The supernatant was
then allowed to incubate overnight at 4uC with mouse IgG (Dako)
or mouse anti-integrin av (P2W7) (Santa Cruz Biotechnology, CA).
50 ml of Dynabeads Protein G (Invitrogen, CA) were added for 1 h
at 4uC with rotation. DNA-protein complexes were recovered from
beads by washing with Low Salt Immune Complex Wash Buffer
(0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCL,
pH 8.1, 150 mM NaCl), High Salt Immune Complex Wash Buffer
(0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCL,
pH 8.1, 500 mM NaCl), LiCl Immune Complex Wash Buffer
(0.25 M LiCl, 1% IGEPAL-CA630, 1% deoxycholic acid, 1 mM
EDTA, 10 mMTris,pH 8.1)(onewasheach) and two washesusing
TE Buffer (10 mM Tris-HCL, 1 mM EDTA, pH 6.0). Samples
were eluted twice with 100 ml elution buffer (20 ml 10% SDS, 20 ml
1 M NaHCO3 and 160 ml sterile water). To reverse crosslinking,
samples were incubated at 65uC for 6 hours or overnight with 8 ml
5 M NaCl. One ml RNase A was added for 30 min at 37uC before
incubating at 45uC for 1–2 hours with 4 ml 0.5 M EDTA, 8 ml1M
Tris-HCL, and 1 ml Proteinase K. DNA was then purified using a
Figure 3. Integrin avb3 mediates T4-induced PCNA accumulation in lung cancer cells. A. Non-small cell carcinoma NCI-H522 cells and
B. small cell NCI-H510A cells were each treated with T4 (10
27 M) in the presence or absence of RGD peptide (50–500 nM) or RGE peptide (500 nM) for
24 h. T4-induced PCNA expression was inhibited by the RGD peptide, but not by a control (RGE) peptide, indicating that interaction with the integrin
at or near the RGD binding site is required for the proliferative effect of thyroid hormone to be seen. *p,0.05,* * p,0.01 compared with control;
+p,0.05 compared with cells treated without RGD. C. Non-small cell carcinoma NCI-H522 cells were each treated with anti-avb3 (0.001 mg/ml–
0.1 mg/ml) or anti-avb5 (0.1 mg/ml) antibody for 24 h and then with T4 (10
27 M) for 24 h. Anti-avb3, but not anti-avb5, blocked T4-induced PCNA
accumulation. This effect was antibody dose-responsive. Lamin-B immunoblots served as loading controls for the nuclear fractions used in these
assays. *p,0.05,* * p,0.01 compared with control; +p,0.05 compared with and without anti-avb3.
doi:10.1371/journal.pone.0027547.g003
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Quantitative PCR. 5 ml of DNA were combined with 10 mlo fP e r f e c t a
SYBR Green FastMix (Quanta Biosciences, MD), 0.3 mle a c ho f
20 mM forward and reverse primers, and 4.7 ml DNase/RNase free
water in a MicroAmp
TM Optical 384-Well Reaction Plate (Applied
Biosystems). The reactions were performed in an ABI Prism 7900 HT
SDS instrument (Applied Biosystems) using the following conditions:
2m i na t5 0 uC, 10 min at 95uC,40 cycles of15 s at 95uC,and 1 min at
60uC. Data were analyzed with the 7900 HT Sequence Detection
Systems Software (version 2.2.3, Applied Biosystems). Primer
s e q u e n c e sf o rp r o m o t e ro fERa were (59 TAACCTCGGGC-
TGTGCTCTT 39 [forward] and 59 TTCCCTTGGATCTGATG-
CAGTAG 39 [reverse]) [21]. Primers for PIG3 [59-CAGGACTGT-
CAGGAGGAGGCGAGTGATAAGG-39(forward) and 59-GTGC-
GATTC-TAGCTCTCACTTCAAGGAGAGG-39 (reverse)] were
used as a negative control for the ChIP assay of integrin av.
Thymidine incorporation
Aliquots of cells were incubated with 1 mCi [
3H]-thymidine
(final concentration, 13 nM) in a 24-well culture tray for 16 h.
Cells were then washed twice with cold PBS; 5% TCA (1 mL) was
then added and the plate was held at 4uC for 30 min. The
precipitate was washed twice with cold ethanol, after which 2%
SDS (1 ml) was added to each well and the TCA-precipitable
radioactivity was quantitated in a liquid scintillation counter.
Confocal microscopy
Exponentially growing NCI-H522 cells were seeded in a slide
chamber. After exposure of cells to medium with 0.25% hormone-
stripped FBS for 2 d, cells were treated with 10
27 MT 4, tetrac or
both for 24 h. Cells were fixed with 5% formaldehyde in acetone
for 5 min, then permeabilized in 100% methanol for 10 min and
rehydrated in 90% methanol for 30 min. The cells were incubated
Figure 4. T4 stimulates nuclear accumulation of phosphorylated ERa.A .The expression of ERa in NCI-H522 non-small cell lung cancer cells
and small cell NCI-H510A cells, studied by RT-PCR, revealed that the NCI-H522 cells contained more ERa than the NCI-H510A cells. B. Non-small cell
NCI-H522 cells were treated with T4 (10
27 M) and/or tetrac (10
27 M) for 24 h, and then examined by confocal microscopy. Nuclear chromosomal
material is indicated by the red color and phosphorylated ERa (pERa) by a green color. T4 caused accumulation of phosphoERa (pERa, green) in cell
nuclei (red) producing a yellow color due to the superimposition of red and green. With the addition of tetrac, the nuclear accumulation of pERa was
less evident in T4-treated cells, while tetrac, alone, did not cause an increase in nuclear accumulation of ERa. Cells were viewed at 2506magnification.
C. Cells were treated with or without T4 (10
27 M) for 24 h, then fixed and harvested for ChIP as described in Materials and Methods.
Immunoprecipitation was performed with anti-integrin av antibody and mouse IgG was used as a negative control (upper panel). Cells were treated
with T4 (10
27 M) in the presence or absence of ICI (5 nM) for 24 h, then fixed and harvested for ChIP as described in Materials and Methods.
Immunoprecipitation was performed with anti-integrin av antibody. The primer used was the ERa promoter sequence. **p,0.01 compared with
control; ++p,0.01 comparing samples with and without ICI.
doi:10.1371/journal.pone.0027547.g004
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PLoS ONE | www.plosone.org 5 November 2011 | Volume 6 | Issue 11 | e27547Figure 5. Effect of ICI 182,780 on cell proliferation induced by T4 in NCI-H522 cells. A. Non-small cell lung cancer NCI-H522 cells were
treated with T3 or T4 (10
27 M, 24 h) in the presence or absence of ICI 182,780 (ICI), an ER antagonist (0.05–5 nM). ICI inhibited phosphorylation of ERa,
ERK1/2 activation, and the proliferative effect (PCNA) of T4 in these cells. However, the action of T3 was minimally affected by ICI, except for
diminution in pERK1/2 levels. *p,0.05,* * p,0.01 compared with control; +p,0.05 comparison with and without ICI. B. NCI-H522 cells cultured in
0.25% hormone-stripped serum-containing medium for 2 d were then placed in 10% stripped serum-containing medium and treated with ICI (5 nM)
for 30 min prior to treatment with thyroid hormone (10
27 MT 4 and T3) for 24 h. 1 mCi [
3H]-thymidine was added simultaneously with thyroid
hormone for 24 h prior to harvest for radiolabeled thymidine incorporation assay. The results of these studies confirm the studies in Fig. 5A, showing
that T4-induced cell proliferation is dependent on activation of ERa, whereas cell proliferation stimulated by T3 is independent of ERa
phosphorylation. *p,0.05,* * p,0.01 compared with control; ++p,0.01 compared with and without ICI. C. NCI-H522 cells were treated with anti-ERa
Thyroid Hormone Induces Lung Cancer Proliferation
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ERa (phospho-ER), followed by Alexa 488-labeled goat anti-
mouse antibody and the signal was revealed with the Histostain SP
kit, as recommended by the manufacturer (Zymed, South San
Francisco, CA). Nuclei were stained with TO-PRO-3 iodide
(Molecular Probes, Eugene, OR), and the cells then examined
under 2506magnification.
Data analysis and statistics
Immunoblot and nucleotide densities were measured with a
Storm 860 phosphorimager, followed by analysis with Image-
Quant software (Molecular Dynamics, Sunnyvale, CA). Student’s t
test, with P,0.05 as the threshold for significance, was used to
evaluate the significance of the hormone and inhibitor effects.
Results
Thyroid hormone stimulates cell proliferation in human
lung cancer cells
In a concentration-dependent manner, T4 induced PCNA
accumulation in NCI-H522 non-small cell lung carcinoma cells
(Fig. 1A). Maximum effects were seen at 10
28 to 10
27 M total
hormone concentration; in the medium/buffer systems we use,
such concentrations yield physiological free T4 levels [11]. T3 also
increased PCNA abundance in NCI-H522 cells (Fig. 1B), but the
effective hormone concentrations exceeded physiologic levels.
Confirmation of the effects of T4 and T3 on PCNA was obtained
in thymidine incorporation studies in non-small cell NCI-H522
lung cancer cells as well as in small cell NCI-H510A cancer cells
(Fig. 1C). Because we have shown that thyroid hormones bind to a
receptor on integrin avb3, we investigated whether integrin avb3
was expressed in NCI-H522 and NCI-H510A cells. Human
ovarian OVCAR-3 cells were used as a positive control [22].
Results shown in Fig. 1D indicate that both lung cancer cell lines
express integrin avb3. Although integrin av is expressed to a
similar degree in both cell lines, the expression of integrin b3i n
NCI-H510A cells is far less than that in NCI-H522 cells.
Integrin avb3 contributes to thyroid hormone-induced
proliferation in lung cancer cells
Non-small cell lung carcinoma NCI-H522 cells were pretreated
with 10
27 MT 4 or T3, in either the presence or absence of tetrac.
Thyroid hormone-induced PCNA expression and ERK1/2
activation were blocked by tetrac (Fig. 2A). Tetrac itself did not
induce PCNA expression. Similar results were observed in small
cell lung cancer NCI-H510A cells in which tetrac blocked thyroid
hormone-induced ERK1/2 activation and PCNA expression
(Fig. 2B).
NCI-H522 cells were pretreated with either RGD peptide or
RGE peptide for 24 h prior to incubation with 10
27 MT 4 for
24 h. The RGD peptide inhibited thyroid hormone-induced
PCNA expression by these non-small cells in a dose-responsive
manner, whereas the control RGE peptide had no effect on T4-
induced PCNA expression (Fig. 3A). Similar results were
observed in small cell lung cancer NCI-H510A cells (Fig. 3B).
We further confirmed that the integrin avb3 is the plasma
membrane binding site for T4 by treatment of cells with
anti-integrin avb3. Integrin avb5 antibody served as a control.
Only the integrin avb3 antibody blocked thyroid hormone-
induced PCNA expression in NCI-H522 cells (Fig. 3C). These
results and other recent studies of the integrin [16,17,18]
implicate the plasma membrane integrin thyroid hormone
receptor in the proliferative effects of iodothyronines on cancer
cells and on angiogenesis.
Thyroid hormone causes phosphorylation of ERa and
transfer of that receptor from the cytosol to nuclei of
treated cells
The estrogen receptor ERa is variably expressed in non-small
cell and small cell lung cancer cell lines, as shown in Fig. 4A. NCI-
H522 cells expressed a greater level of this receptor with 2–5 times
the level in the NCI-H510A non-small cell line (Fig. 4A).
Thyroxine is known to induce ERa phosphorylation in human
breast cancer MCF-7 cells [7]. We demonstrate by confocal
microscopy in Fig. 4B that thyroid hormone causes nuclear
accumulation of phosphorylated ERa in non-small cell NCI-H522
lung cancer cells. The nuclear accumulation of phosphorylated
ERa caused by T4 (shown in green) co-localized with nuclear
chromatin (shown in red), yielding a yellow color. This action of
T4 was inhibited by co-incubation of cells with T4 and tetrac,
although tetrac alone had little effect (Fig. 4B). A specific
inhibitor of ERa activation, ICI 182,780 (ICI), blocks thyroid
hormone-stimulated thymidine uptake in human breast cancer
MCF-7 cells, suggesting that T4-induced proliferation of MCF-7
cells is dependent on the presence of ERa [7]. Thyroid hormone
(T4) induces integrin av translocation into nuclei and association
with p300 [23] suggesting that nuclear integrin av may play a
role in thyroid hormone-dependent gene transcription. In order
to examine the relationship between integrin ava n dE R a on
gene regulation, NCI-H522 cells were treated with T4 in the
presence or absence of ICI. A chromatin immunoprecipitation
assay (ChIP) was conducted by using anti-integrin ava n t i b o d y .
Mouse IgG was used as a negative control. T4 increased integrin
av binding to the ERa promoter except in the sample
immunoprecipitated with mouse IgG (Fig. 4C, upper panel).
The binding of integrin avt ot h eERa promoter sequence is
specific, as with the use of primer sequences of the PIG3
promoter we were unable to produce a visible DNA sequence
(results not shown). The T4-activated integrin avf o r m e da
complex with the ERa promoter, which was reduced by ICI
(Fig. 4C, lower panel). These results suggest that crosstalk
between integrin avb3a n dE R a is involved in T4-dependent
transcription.
Phosphorylation of nuclear ERa parallels thyroid
hormone-induced proliferation in lung cancer cells
We further studied the role of ERa on thyroid hormone-
induced proliferation in lung cancer cells. As shown in Fig. 4A
both NCI-H522 and NCI-H510A lung cancer cell lines express
ERa (NCI-H522&NCI-H510A). When non-small cell carcinoma
NCI-H522 cells were treated with thyroid hormone (T4 or T3) for
24 h in the presence or absence of 0.05–5 nM ICI, both hormones
caused activation of ERK1/2 and PCNA accumulation (Fig. 5A).
The T4 effects on nuclear accumulation of pERa, pERK1/2 and
or -ERb antibody (0.1 mg/ml) for 24 h and ICI (5 nM) for 30 min prior to treatment with T4 (10
27 M) for either 30 min or 24 h. Nuclear proteins were
separated by SDS-PAGE and western blotting analyses carried out with anti-pERK1/2 or -PCNA antibodies. Thyroid hormone-induced ERK1/2
activation and PCNA accumulation was affected by ICI but not by either anti-ERa or anti-ERb antibody. **p,0.01 compared with control; ++p,0.01
compared with and without ICI.
doi:10.1371/journal.pone.0027547.g005
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indicating a direct association with activation (phosphorylation) of
ERa. In contrast, T3 minimally increased ERa phosphorylation
and cell proliferation, and these were not affected by ICI; this
inhibitor only suppressed ERK1/2 activation by T3. Similar
results were observed by using another inhibitor of ERa,
tamoxifen, which inhibited T4-induced ERK1/2 activation and
PCNA accumulation (results not shown). Findings in the
thymidine incorporation studies (Fig. 5B) paralleled results of
PCNA immunoblots in that cell proliferation was inhibited by ICI
in the presence of T4, but not in the presence of T3.
Studies have shown that ERa also exists on the cell membrane
[24,25]. To exclude the possibility that membrane ERa is
activated by thyroid hormone and translocates into the nucleus,
experiments were conducted to examine if membrane ERa is
involved in thyroxine’s action. NCI-H522 cells were pre-treated
for 24 h with anti-ERa or anti-ERb as controls prior to addition of
ICI and 10
27 MT 4. Cells were harvested and activation of
ERK1/2 and increased expression of PCNA by T4 was evaluated.
T4-induced ERK1/2 activation and PCNA expression was
inhibited by ICI but not by either anti-ERa or anti-ERb antibody
(Fig. 5C). The combination of ICI and antibody did not alter the
inhibitory effect of ICI. These results indicated that the T4-
induced signal activates cytosolic ERa and translocates phosphor-
ylated ERa into nuclei accompanied by activated ERK1/2.
Effects of the ICI compound were also studied in small cell
carcinoma (NCI-H510A) cells (Fig. 6A). Because these cells
contain less ERa than the NCI-H522 cells, immunoprecipitation
of ERa and subsequent protein electrophoresis were used to
enhance the content of ERa present in experimental samples.
Both T4 and T3 induced ERK1/2 activation and PCNA
expression, but only T4 caused ERa phosphorylation in these
cells (Fig. 6A). The T4-induced effects were all inhibited by ICI,
whereas there was little effect of ICI on T3-induced ERK1/2
activation and PCNA accumulation. Similar results were observed
with thyroid hormone-induced thymidine incorporation studies
(Fig. 6B) in which the proliferative effect of T4 was inhibited by
ICI, but cell proliferation in the presence of T3 was not affected by
ICI. The differences between the effects of T4 and T3 in NCI-
H510A cells were not surprising, given our recent description of
the complexity of the thyroid hormone binding site on the integrin
[16] and the ability of the receptor to distinguish between T4 and
T3 and to generate discrete downstream signals in response to the
two thyroid hormones. These results in NCI-H510A cells do
indicate that T3 stimulates cell proliferation by a mechanism that is
independent of ERa.
Discussion
Acting at the cell surface integrin avb3 receptor for thyroid
hormone, T4 and T3 induced cell proliferation in the human lung
cancer cell lines studied in the present report. Thyroid hormone-
induced proliferation in these cells is blocked by tetrac, an
analogue of thyroid hormone which has been shown to interfere
with the binding of the thyroid hormones T4 and T3 to integrin
avb3 [11]. This hormonal action on lung cancer cells is also
blocked by RGD peptide and by antibody to integrin avb3,
confirming that cell surface integrin avb3 is the initiation site of
the proliferative action of thyroid hormone. These lung cancer
results are consistent with our previous observations of induc-
tion by thyroid hormones of cell proliferation in human breast
cancer [7], human thyroid cancer [9], human glioma [26] and rat
glioma cells [8]. In such tumor cells, physiologic concentrations of
Figure 6. Effect of ICI 182,780 (ICI) on cell proliferation induced
by T4 in NCI-H510A cells. A. Small cell carcinoma NCI-H510A cells,
which express low levels of ERa, were treated with T4 or T3 (10
27 M,
24 h) in the presence or absence of ICI (2 or 20 nM). This inhibitor
suppressed ERK1/2 activation, phosphorylation of ERa and cell
proliferation by T4—but not by T3—in NCI-H510A cells. ICI did not
inhibit any actions of T3. *p,0.05,* * p,0.01 compared with control.
+p,0.05, ++p,0.01 compared with and without ICI. B. NCI-H510A cells
were treated with ICI (20 nM) for 30 min prior to treatment with T4 or T3
(1027 M) for 24 h in the presence of radiolabeled thymidine. The
results of these studies in small cell lung cancer cells are similar to the
results of studies in non-small cell lung cancer cells (Fig. 5), again
showing that the proliferative action of T3, in contrast to that of T4,i s
not mediated by activation of ERa, in contrast to the proliferative action
of T4 which is blocked by ICI, the ERa inhibitor. **p,0.01 compared with
control; ++p,0.01 compared with and without ICI.
doi:10.1371/journal.pone.0027547.g006
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growth factor.
There is crosstalk between integrin avb3 and several polypep-
tide growth factor receptors on the plasma membrane that appear
to be clustered with the integrin [27,28,29]. Thyroid hormone also
nongenomically affects the behavior of the epidermal growth
factor receptor [30]. Furthermore, we have previously shown that
tetrac modulates such crosstalk between hormone and growth
factor in the case of TGFa as well [30]. In addition to crosstalk,
however, thyroid hormone can nongenomically signal downstream
within the cell to the classic nuclear thyroid hormone receptor
(TR); that is, from the cell surface, the hormone can alter the
activity state of a nuclear thyroid hormone receptor (TRb1) via
control of ERK1/ERK2-mediated serine phosphorylation of the
nucleoprotein [25,31].
What was somewhat surprising in studies of downstream
signaling induced by T4 several years ago was that this hormone
could, through ERK1/2, trespass into the domain of steroids and
promote phosphorylation of Ser-118 of ERa in human breast
cancer cells [7]. This mimicked precisely the action of estradiol
and was important to the proliferative action of thyroid hormone
on these breast cancer cells. A natural extension of this finding was
to examine the possibility that in ERa-bearing lung cancer cells,
the proliferative effect of thyroid hormone was also ER-mediated.
The present studies confirm that this is the case for T4. On the
other hand, while T3 can stimulate lung cancer cell proliferation at
above-physiologic hormone concentrations, this action of T3
appears not to require ER. We have recently shown that the
integrin receptor for thyroid hormone readily distinguishes
between T4 and T3 and can generate different or similar signals
from each hormone that result in discrete or similar downstream
biologic effects [17,18]. We have also recently demonstrated that
the androgen dihydrotestosterone can stimulate breast cancer cell
proliferation by an ERa-dependent mechanism when the receptor
is present and an ERa-independent process when tumor cells lack
that receptor [32].
It is clear that TR in the nuclear compartment does not play a
primary role in the integrin avb3-initiated actions of thyroid
hormone [1]. However, overexpression of TRb1 can be involved
in thyroid hormone (T3)-induced inhibition of proliferation of
certain cells [33] and mutations of nuclear TR can result in
interesting models of thyroid carcinoma [1]. In addition, nuclear
TR isoforms that reside in cytoplasm can participate in
nongenomic actions of thyroid hormone [34,35], at least one of
which modulates downstream the expression of the hypoxia-inducible
factor- 1a (HIF-1a) gene [36]. We have also shown that thyroid
hormone can act at the cell surface on the integrin receptor and
influence expression of HIF-1a [17].
Further understanding of the integrin receptor for thyroid
hormone may permit the receptor to emerge as an anti-
proliferation target. Because of the anti-angiogenic properties of
tetrac that are expressed via the avb3 receptor, this hormone
analogue has more than one attractive feature in the setting of
cancer [17]. The agent may also chemosensitize certain tumor
cells that are chemoresistant [37]. The present studies suggest that
certain lung cancers may be susceptible to therapeutic agents that
act at the integrin iodothyronine receptor, such as tetrac.
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